Skip to main content

Table 5 Correlations between CASC16 polymorphisms and clinical characteristics of patients with breast cancer (adjusted by age)

From: The association of CASC16 variants with breast Cancer risk in a northwest Chinese female population

SNP

Genotype

Clinical stage

Tumor size (cm)

LN metastasis

III,IV/I,II

OR (95% CI)

p-value

> 2 / ≤2

OR (95% CI)

p-value

Positive/Negative

OR (95% CI)

p-value

rs3803662

A

213/447

1

 

568/191

1

 

454/450

1

 

G

87/195

0.94 (0.69–1.27)

0.668

250/87

0.97 (0.72–1.30)

0.819

192/212

0.90 (0.71–1.14)

0.368

AA

71/151

1

 

191/67

1

 

153/149

1

 

GA

71/145

1.02 (0.68–1.53)

0.917

186/57

1.13 (0.0.75–1.71)

0.546

148/152

0.95 (0.69–1.31)

0.744

GG

8/25

0.66 (0.28–1.53)

0.331

32/15

0.73 (0.37–1.44)

0.367

22/30

0.71 (0.39–1.30)

0.270

GA + GG

79/170

0.97 (0.66–1.43)

0.869

218/72

1.05 (0.71–1.55)

0.803

170/182

0.91 (0.67–1.24)

0.547

rs4784227

C

206/479

1

 

589/200

1

 

447/491

1

 

T

94/163

1.34 (0.99–1.81)

0.056

219/76

0.98 (0.72–1.33)

0.889

197/161

1.34 (1.05–1.72)

0.018

CC

73/177

1

 

220/69

1

 

155/185

1

 

TC

60/125

1.19 (0.79–1.81)

0.400

149/62

0.77 (0.51–1.15)

0.194

137/121

1.35 (0.98–1.87)

0.069

TT

17/19

2.19 (1.08–4.46)

0.031

35/7

1.59 (0.67–3.73)

0.292

30/20

1.79 (0.98–3.28)

0.059

TC + TT

77/144

1.33 (0.90–1.96)

0.155

184/69

0.85 (0.58–1.25)

0.410

167/141

1.41 (1.04–1.93)

0.028

rs45544231

G

245/532

1

 

661/209

1

 

526/522

1

 

C

55/110

1.09 (0.76–1.55)

0.652

157/69

0.72 (0.52–0.99)

0.045

120/140

0.85 (0.65–1.12)

0.244

GG

100/223

1

 

267/86

1

 

215/211

1

 

CG

45/86

1.14 (0.74–1.76)

0.549

127/37

1.09 (0.70–1.70)

0.693

96/100

0.94 (0.67–1.32)

0.726

CC

5/120

0.89 (0.30–2.61)

0.833

15/16

0.29 (0.14–0.61)

0.001

12/20

0.59 (0.28–1.23)

0.160

CG + CC

50/206

1.11 (0.73–1.69)

0.621

142/53

0.85 (0.57–1.27)

0.424

108/120

0.88 (0.64–1.22)

0.450

rs12922061

C

208/470

1

 

583/203

1

 

444/490

1

 

T

92/172

1.21 (0.89–1.63)

0.217

235/75

1.09 (0.80–1.48)

0.576

202/172

1.30 (1.02–1.65)

0.034

CC

73/172

1

 

212/72

1

 

152/181

1

 

TC

62/126

1.18 (0.78–1.78)

0.424

159/59

0.93 (0.62–1.34)

0.709

140/128

1.30 (0.94–1.80)

0.108

TT

15/23

1.58 (0.78–3.20)

0.209

38/8

1.64 (0.73–3.68)

0.232

31/22

1.68 (0.93–3.02)

0.084

TC + TT

77/149

1.24 (0.84–1.84)

0.275

197/67

1.24 (0.84–1.84)

0.955

171/150

1.34 (0.99–1.85)

0.051

rs3112612

A

245/532

1

 

661/207

1

 

526/520

1

 

G

55/110

1.09 (0.76–1.55)

0.652

157/69

0.71 (0.52–0.98)

0.039

120/140

0.85 (0.65–1.11)

0.233

AA

100/223

1

 

267/85

1

 

215/210

1

 

GA

45/86

1.14 (0.74–1.76)

0.549

127/37

1.08 (0.69–1.68)

0.739

96/100

0.94 (0.67–1.31)

0.702

GG

5/12

0.89 (0.30–2.61)

0.833

15/16

0.28 (0.14–0.60)

0.001

12/20

0.58 (0.28–1.23)

0.155

GA + GG

50/98

1.11 (0.73–1.69)

0.621

142/53

0.84 (0.56–1.25)

0.386

108/120

0.88 (0.64–1.21)

0.429

  1. p values were calculated by unconditional logistic regression adjusted by age; p < 0.05 indicates statistical significance
  2. LN lymph node
  3. Highlighted in bold indicates the significant association between SNPs and breast cancer risk
Back to article page

Molecular Medicine

ISSN: 1528-3658